Research programme: peptide based therapeutics - Nimble Therapeutics/Incyte Therapeutics
Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Nimble Therapeutics
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Unspecified in USA
- 15 Sep 2021 Nimble Therapeutics expands the research collaboration with Incyte, to include discovery of additional peptide therapies
- 05 Oct 2020 Nimble Therapeutics and Incyte agree to co-develop peptide-based therapeutics